2023年2月4日，据欧共体调味品稳定局（EFSA）传闻，欧共体健康、最新科技调味品和蛋白质食物出现过敏现象源（NDA）探析队伍就扩充采用2'-岩藻糖基乳糖（2'-FL）和乳糖-N-新四糖（lacto-N-neotetraose）（LNnT）做最新科技调味品用以新生婴儿调味品补冲剂中的稳定性刊登科学研究提出的意见。 路过开展，专家团队领导组测得论证，在建意的服用情况下，新生婴儿服用含2'-FL或LNnT的莒养增幅商品是安全防护的。部门原稿通讯稿相应：

Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the safety of the extensions of use of the authorised novel foods (NFs) 2’-fucosyllactose (2’-FL) and lacto-N-neotetraose (LNnT) in food supplements (FS) for infants pursuant to Regulation (EU) 2015/2283. The NFs are produced by fermentation with genetically modified strains of Escherichia coli K-12 and already Ｉncluded in the EU list of NFs. The applicant stated that no changes in the production process or the identity of the NFs occurred. The applicant proposes an extension of use of the NF containing 2’-FL in FS intended for infants (< 1 year), at a maximum use level of 1.2 g/day. The applicant also proposes an extension of use of LNnT in FS intended for infants, at a maximum use level of 0.6 g/day. The intake of 2’-FL per kg body weight from the proposed maximum use levels in FS for infants is lower than the lowest estimated mean intake of naturally occurring 2’-FL from human milk. Similarly, the intake of LNnT per kg body weight is lower than the highest estimated mean intake of naturally occurring 2’-FL from human milk. Furthermore, the Panel notes that the proposed uses of 2’-FL in FS for infants are lower than the estimated intake from the already authorised uses of the NF for the same population group. The Panel also notes that the proposed uses of LNnT in FS for infants are similar to the estimated intake from the already authorised uses of the NF for the same population group. The Panel concludes that the use of the NFs containing 2’-FL or LNnT in FS for infants is safe under the proposed conditions of use.